Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCYL-L-ISOLEUCINE is a synthetic small molecule characterized as a peptidyl epoxide. This compound functions as a selective, irreversible inhibitor of cysteine proteases. Its mechanism of action involves the covalent alkylation of the active-site thiol of target cysteine proteases, forming a stable enzyme-inhibitor complex. The epoxide moiety acts as an electrophilic 'warhead', while the L-isoleucyl-L-isoleucine dipeptide sequence contributes to the specificity of the inhibitor. Compounds of this class are investigated for their potential in treating various conditions where cysteine proteases play a pathological role, including certain cancers, inflammatory diseases, and viral infections such as HIV.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCYL-L-ISOLEUCINE.